One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry
Por:
Ruiz-Nodar, J, Esteve-Pastor, M, Rivera-Caravaca, J, Sandin, M, Lozano, T, Vicente-Ibarra, N, Orenes-Pinero, E, Macias, M, Pernias, V, Carrillo, L, Candela, E, Veliz, A, Tello-Montoliu, A, Martinez, J and Marin, F
Publicada:
1 jun 2020
Ahead of Print:
1 feb 2020
Resumen:
Background Prasugrel and ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with acute coronary syndrome (ACS). However, the long-term prognosis and different clinical characteristics related to the type of antiplatelet prescription in current clinical practice ACS patients have not been analysed in depth. The objective of this study was to analyse the clinical profile of ACS and the efficacy and safety of novel oral P2Y(12) inhibitors in current clinical practice patients discharged afterACS.
Methods We collected data from the ACHILLES registry, and an observational, prospective and multicentre registry of patients discharged after ACS. We analysed baseline characteristics, clinical profile and therapy during ACS admission and compared with the different treatments at discharge. After 1 year of follow-up, ischaemic and major bleeding events were analysed. Multivariate Cox regression analysis and Kaplan Meier curves were also plotted.
Results Of 1717 consecutive patients, 1294 (75.4%) were discharged with a P2Y12 inhibitor without oral anticoagulation. Novel oral P2Y(12) inhibitors were indicated in 47%. Patients treated with clopidogrel were elderly (69.1 +/- 13.4 vs 60.4 +/- 11.5 years; P < .001) and had a higher prevalence of cardiovascular risk factors. GRACE and CRUSADE scores were higher in the clopidogrel than in novel oral P2Y(12) inhibitors group (P < .001). After 1 year of follow-up, 64(5.0%/year) patients had a new myocardial infarction, 127(10.0%/year) had a major adverse cardiovascular event (MACE) and 78(6.1%/year) died. Patients treated with clopidogrel had a significantly higher annual rate of cardiovascular mortality, MACE and all-cause mortality (allP < .001) without differences in major bleeding (P = .587) compared with novel oral P2Y(12) inhibitors. After multivariate adjustment for the main clinical variables related to adverse prognosis in ACS patients, the discharge with novel oral P2Y(12) inhibitors therapy was independently associated with lower risk of all-cause mortality (HR0.49, 95% CI [0.24-0.98], P = .044) and lower risk of MACE (HR0.64, 95% CI [0.41-0.98], P = .044).
Conclusions In this prospective, observational and current clinical practice ACS registry, the use of novel oral P2Y(12) inhibitors was associated with a reduction in adverse events compared with clopidogrel in patients with ACS. Novel oral P2Y(12) inhibitors prescription at discharge was independently associated with lower all-cause mortality and MACE without differences in bleeding events. However, clopidogrel remained the most common P2Y12 inhibitor employed for ACS, especially in older and high-risk patients.
Filiaciones:
Ruiz-Nodar, J:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
Esteve-Pastor, M:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Rivera-Caravaca, J:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Sandin, M:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
Lozano, T:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
:
Hosp Gen Univ Elche, Dept Cardiol, Alicante, Spain
Orenes-Pinero, E:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Macias, M:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
:
Hosp Gen Univ Elche, Dept Cardiol, Alicante, Spain
Carrillo, L:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
Candela, E:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
Veliz, A:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Tello-Montoliu, A:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Martinez, J:
Hosp Gen Univ Alicante, Dept Cardiol, Alicante 03010, Spain
Inst Invest Sanit & Biomed Alicante, Alicante, Spain
Marin, F:
Hosp Clin Univ Virgen Arrixaca, Dept Cardiol, Inst Murciano Invest Biosanit, CIBER CV, Murcia, Spain
Green Published, Bronze
|